Lipoxin A4 (LXA4) was competitive with [3H]leukotriene D4 (LTD4) for speciflc binding to cultured rat glomerular mesangial cells. Half-maximal inhibition was obtained with 100 nM LXA4, compared with 10 nM for unlabeled LTD4. At 10 and 50 nM LXA4 induced low, but significant, increases in mesangial-cell inositol trisphosphate generation:
48% and 44% increases as compared to vehicle controls, respectively (compared with 146% and 106% increments obtained for equimolar LTD4), which were abolished in the presence of 100-fold concentrations of the LTD4 receptor antagonist, SKF 104353. In addition, exposure to 100 nM LXA4 prevented mesangial cell inositol trisphosphate generation induced by 10 nM LTD4. To test the in vivo relevance of these results, we established a dose-response curve for the reducing effects of intrarenal arterial LTD4 on glomerular filtration rate and renal plasma flow in anesthetized rats (LTD4 doses were 0.5, 7.0, 14.0, and 20.0 gig/kg per min) without or with LXA4 at 1 ,ug/kg per min. Mean percent decreases in glomerular filtration rate/renal plasma flow during LTD4 administration were 27*/24, 25*/40*, 70*/65*, and 73*/70* at the above doses, respectively (*P < 0.05 versus baseline). With LXA4, these values were as follows: 9/20*, 11/37*, 42*/51*, and 50*/68*, the latter value representing a shift in the LTD4/glomerular filtration rate dose-response curve. Thus, LXA4 competes for [3HJLTD4 binding to mesangial cells, its presence prevents LTD4-induced inositol trisphosphate generation, and its own stimulation of mesangial-cell inositol trisphosphate is blocked by an LTD4 receptor antagonist. In vivo, LXA4 antagonizes LTD4-induced falls in glomerular filtration rate but not renal plasma flow, implying prevention of LTD4-mediated reductions in the glomerular ultrafiltration coefficient, a consequence of mesangial-cell contraction. These results suggest that LTD4 and LXA4 interact at a common site on rat mesangial cells at which LXA4 provokes partial agonist responses and competitively antagonizes both the cellular and physiological actions of LTD4. Moreover, these results provide evidence for a potential counterregulatory interaction between leukotrienes and lipoxins that may be relevant during glomerular inflammation.
Lipoxygenase products of arachidonic acid display a diverse array of biological activities (1) and may participate in mediating the functional consequences of glomerular inflammatory injury (2) . When administered selectively into the renal artery of anesthetized rats, leukotriene D4 [LTD4) exerts vasoconstrictor effects, and lipoxin A4 [LXA4; (5S,6R,15S)trihydroxy-7,9,13-trans-11-cis-icosatetraenoic acid] elicits vasodilator responses in renal arterioles, but both reduce the glomerular capillary ultrafiltration coefficient (Kf) (3, 4) . The latter results from the concerted contractile action of smooth muscle-containing glomerular mesangial cells, which reduces the glomerular capillary area available for ultrafiltration and, hence, Kf (5, 6) . We have recently characterized the binding of [3H]LTD4 to rat glomerular mesangial cells and the resultant intracellular signal-transduction pathways. § Because the orientation of the polar groups is similar in the peptidoleukotrienes and LXA4 (i.e., 5S,6R-) (8, 9) and is a crucial requirement for biologic activity of these icosanoids (1, (8) (9) (10) (11) , we investigated whether LXA4-induced falls in Kf were due, in part, to its action on the mesangial-cell LTD4 receptor. Ci/mmol) were obtained from New England Nuclear. All icosanoids were stored under argon at -70°C in methanol, and their purity and quantity were verified periodically by UV scanning and HPLC.
METHODS
Mesangial Cell Culture. Rat mesangial cells were isolated and cultured as described (6) . Briefly, kidneys were excised from two young Sprague-Dawley rats under sterile conditions, and the cortices were removed, minced, and washed several times in Hanks' balanced salt solution containing 10 mM Hepes (pH 7.4), amphotericin (0.25 ,ug/ml), and gentamicin (50 ug/ml). The tissue was then passed through consecutive sterilized stainless mesh filters with pore sizes of 212 ,um and 150 ,um and then onto the final mesh of 75 ,m. The isolated glomeruli were harvested from the surface ofthe 75-,um filter and washed twice with the Hanks' medium. The glomeruli were suspended in RPMI 1640 medium with 15% fetal bovine serum (GIBCO), penicillin (100 units/ml), and streptomycin (100 /.g/ml) (GIBCO), plated into 100-mm cell culture Petri dishes, and incubated at 370C in a humidified atmosphere of95% air/5% CO2. Mesangial cell colonies were subcultured in 60-mm culture dishes, and experiments were carried out on cells from passages 2-12. The criteria used to establish the identity of mesangial cells were as described (6) . Cells were routinely grown in RPMI 1640 medium, supplemented with 20% fetal calf serum, penicillin at 100 units/ml, and streptomycin at 100 pAg/ml.
[ (12, 13) . Therefore, experiments were performed in a buffer previously determined to optimize [3H]LTD4 binding (13, 14) , consisting of 20 mM Hepes, 10 mM CaC12, 10 mM MgCl2, 5 mM glycine, and 5 mM cysteine (buffer A). Binding studies were routinely performed at 40C. Cells were washed once with buffer A and then exposed to the appropriate concentration of [3H]LTD4 in buffer A. At the completion of the experiment the experimental medium was removed, and the cells were washed five times with ice-cold buffer. Cells were then dissolved with 1.0 ml of 1.0 M NaOH, neutralized with HCl, dissolved in 10 ml of Aquasol (New England Nuclear), and the bound radioactivity was determined using a scintillation counter (Beckman LTD4 or LXA4 was measured as follows. Plates were washed with Krebs-Ringer solution containing 118 mM NaCI, 4.6 mM KCl, 24.9 mM NaHCO3, 1 mM KH2PO4, 11.1 mM glucose, 1.1 mM MgSO4, 1.0 mM CaC12, 5 mM Hepes, and 0.1% bovine serum albumin, pH 7.4, at 37°C. Various concentrations (0.1-100 nM) of LTD4, LXA4, or LTD4 after preincubation of cells with 100-fold concentration of LXA4 for 10 min were then added in 2 ml of warmed (37°C) KrebsRinger solution, and the cells were incubated for the indicated time. In experiments in which the effect of the LTD4 antagonist, SKF 104353, on inositol phosphate formation was tested, the cells were preincubated with this agent for 10 min before adding agonist (14, 15) . Reactions were terminated by the addition of cold 10o trichloroacetic acid, the supernatants were subjected to ether extraction, and the aqueous phase was titrated to neutral pH using 0. England Nuclear) mixed in a ratio of 3:2:1, respectively, and subjected to separation by HPLC. The latter was performed using established described methodology (17) . The results from both separation techniques revealed indistinguishable differences in the percentage ofrecovered counts (=80%) and the quantitative ratio of the three inositol phosphates separated.
Measurement of Renal Function in Vivo. Experiments were performed on Inactin-anesthetized male Munich-Wistar rats weighing 220-240 g that were surgically prepared according to described protocols (3). Inulin and para-aminohippurate (PAH) clearances were used to measure glomerular filtration rate (GFR) and effective renal plasma flow (RPF). A needle was placed at the root of the left renal artery through which a maintenance infusion of 0.9% NaCl at 0.05 ml/min was initiated. This infusion originated from two separate pumps each delivering at 0.025 ml/min and connected to the renal arterial catheter by means of a three-way connector. Homologous rat plasma was administered i.v. according to a protocol shown previously to maintain euvolemia (3). Intrarenal arterial administration of LTD4 (1 ug/kg per min) results in systemic hemodynamic alterations identical to those we previously reported for leukotrienes C4 and D4 (3, 18) , which included elevation in systemic arterial pressure and progressive loss of plasma volume. To minimize the systemic effects of LTD4 and allow for adequate assessment of renal functional parameters, the rate of infusion of homologous rat plasma was increased upon starting LTD4, and -4-5 ml of plasma were administered throughout the leukotriene infusion. The degree of change in hematocrit varied with the dose of LTD4 (Table 1) . Inulin and para-aminohippurate (PAH) concentrations were determined according to Fuhr et al. (19) and Smith et al. (20) . Two experimental groups were studied as follows. Group I (n = 14): During period 1 clearances were performed during vehicle infusion as described above. During period 2 measurements were repeated during a 20-min infusion of LTD4 delivered through one of the infusion pumps into the left renal artery at doses of 0.5 (n = 4), 7 (n = 3), 14 (n = 3), and 20 (n = 4) ,ug/kg per min. Group II (n = 12): During period 1 clearances were performed during vehicle infusion. In period 2 measurements were repeated during a 20-min infusion of LXA4 infused at a dose of 1 ,g/kg per min. For period 3 the infusion of LXA4 was continued as in period 2 and then LTD4 infusion was initiated through the second pump-again in doses of 0.5 (n = 3), 7 (n = 3), 14 (n -3), and 20 (n = 3) ,ug/kg per min (as in group I).
Analysis of variance with Bonferroni modification for multiple preplanned comparisons was used, within each group and between groups, to compare the changes in various whole kidney and microcirculatory indices that occurred from one period to another. In inositolphospholipid generation studies, increases in [3H]InsP3 cpms in agonist-treated cells were compared to vehicle-treated controls using unpaired Student's t test. Differences were considered significant at a P value < 0.05. All values are reported as mean ± SEM. Inositolphospholipid Hydrolysis in Mesangial Cells. Five seconds after addition of 1 nM (n = 3), 10 nM (n = 6), 50 nM (n = 3), and 100 nM (n = 5) LXA4 to mesangial cells labeled with [3H]inositol, low but significant increases [46 ± 14% (P <0.05), 50 ± 21% (P < 0.05), 44 ± 22% (P < 0.05), and 45 ± 26% (P < 0.05), respectively] in radioactive counts (cpm) corresponding to InsP3 formation by these cells was noted over those in vehicle-treated samples (controls). Addition of 10 nM (n = 5) and 50 nM (n = 4) LTD4 to these cells was associated with 146 ± 20% (P < 0.01) and 106 ± 13% (P < 0.005) increases in [3H]InsP3 counts as compared to controls, values significantly greater than those for LXA4 (P < 0.05). Incubation of the mesangial cells with the LTD4 receptor antagonist, SKF 104353, in concentrations 100-fold in excess of the ligand, followed by addition of LTD4 in the 10-and 50-nM concentrations (n = 3 for each) was (Fig. 2) .
RESULTS
Administration of LTD4 (LTD4 doses of 0.5, 7.0, 14.0, and 20.0 ,ug/kg per min) in group I animals was associated with dose-dependent reductions in the mean values for GFR and RPF summarized in Table 1 . In group II animals, administration of LXA4 was associated with moderate increases in both GFR and RPF in all animals ( (3, 4, 18) . The administration of increased doses of LTD4 in the presence of LXA4, however (group II, period 3) was associated with marked blunting of the LTD4-provoked reduction in GFR (period 2 as compared with period 3) but was without effect on LTD4-induced falls in RPF (Table 1) . Mean percent falls in GFR-RPF during LTD4 administration were 27*/24, 25*/40*, 70*/65*, and 73*/70* at the above doses, respectively (* indicates P < 0.05 versus baseline). In the presence of LXA4, these values were as follows: 9/20*, 11/37*, 42*/51*, and 50*/68*. The dose-response curves for LTD4-induced falls in GFR and RPF without and with LXA4 are depicted in Fig. 3 (3, 18) , and, through these actions, plays an important role in mediating the impairment of glomerular filtration and permselectivity functions in experimental models of glomerulonephritis (2) . In contrast to LTD4, a vasoconstrictor end-product of the 5-lipoxygenation of arachidonic acid in inflammatory cells, LXA4, derived from the interactions of both the 5-and 15-lipoxygenases in these cells, can exert vasodilatory responses. These contrasting effects of leukotrienes and lipoxins on arteriolar vascular smooth muscle have been demonstrated in the hamster cheek pouch (23) , as well as in the rat renal microcirculation (4) . In the latter, however, and in contrast to its vasorelaxant effects on Table 1 for mean absolute values.) Note the shift in GFR, but not RPF, dose-response curves in the presence of LXA4. *, P < 0.05 versus corresponding points in the presence of LXA4. arteriolar smooth muscle, LXA4 appeared to exert paradoxical constrictor actions on glomerular mesangial cells, leading to reductions in Kf (4) . In light of recent studies demonstrating desensitization of leukotriene C4-pretreated guinea pig pulmonary tissue to the contractile actions of LXA4, and in view of structure-function studies suggesting the importance of the 5S,6R configuration for biological activity of peptidoleukotrienes, as well as other icosanoids that contain active groups at carbons-5 and -6 (8-11), we examined the possibility that the effects of LXA4 on mesangial-cell function may result from its interaction with the LTD4 receptor. To this end, we investigated the question at three levels: receptor binding, second-messenger generation (i.e., InsP3), and in vivo physiologic interactions of LTD4 and LXA4.
In early-passage cultured mesangial cells, LXA4 was a potent competitor for [3H]LTD4 binding in a manner similar to that ofunlabeled LTD4 (Fig. 1) (13) , sheep tracheal smooth muscle cells (24) , bovine endothelial cells (25) , and guinea pig lung (26) (27) in dimethyl sulfoxide-differentiated HL-60 myeloid cells. In the present studies, LXA4 elicited similar, though significantly less-potent stimulation of InsP3 generation in mesangial cells, presumably due to occupancy of the LTD4 receptor. That LXA4-induced InsP3 formation is, indeed, a consequence of LTD4 receptor activation is supported by its total abrogation in the presence of a specific LTD4-receptor antagonist, SKF 104353 (Fig. 2) . SKF 104353 is a structural analog of LTD4 and leukotriene E4 that itself is devoid of agonist activity both in vivo (3, 14) and in vitro (14, 15) , and it competes for the binding of homoligands to LTD4/leukotriene E4 receptors in a highly potent and specific manner (15) 400 to 500-fold more effectively than the putative leukotriene antagonist, FPL 55712 (15) . SKF 104353 can antagonize and reverse LTD4 effects in a number oftissues, including human and guinea pig lung (14) , rat basophilic leukemia cells (13) , and renal vasculature (2) . In systems where it has been tested, SKF 104353 competed specifically with [3H]LTD4 for binding to whole cells (13) (14) (15) , as well as cell-membrane fractions (13) (14) (15) , and it shifts the dose-response curves obtained for LTD4-mediated inositolphospholipid hydrolysis, intracellular calcium mobilization, and thromboxane synthesis (13) (14) (15) (Fig. 3) . The vasodilatory and GFR-augmenting effects ofLXA4 (4), on the other hand, are evident in the changes in GFR and RPF seen in group II animals (period 2 versus period 1). Subsequent administration of LTD4 in these rats during continued infusion of LXA4, however, is associated with a dramatic shift in the dose-response for the LTD4-induced falls in GFR (period 2 to period 3 in group II rats). The relative protection against the GFR-depressant action of LTD4 (provided by LXA4) despite absence of any modification of the potent vasoconstrictor action of LTD4 (Fig. 3B) 
